Cancer Cells with Alternative Lengthening of Telomeres Do Not Display a General Hypersensitivity to ATR Inhibition

Katharina I. Deeg, Inn Chung, Caroline Bauer and Karsten Rippe*

Research Group Genome Organization & Function, German Cancer Research Center (DKFZ) and Bioquant Center, Heidelberg, Germany

Telomere maintenance is a hallmark of cancer as it provides cancer cells with cellular immortality. A significant fraction of tumors uses the alternative lengthening of telomeres (ALT) pathway to elongate their telomeres and to gain an unlimited proliferation potential. Since the ALT pathway is unique to cancer cells, it represents a potentially valuable, currently unexploited target for anti-cancer therapies. Recently, it was proposed that ALT renders cells hypersensitive to ataxia telangiectasia- and RAD3-related (ATR) protein inhibitors (Flynn et al., Science 347, 273). Here, we measured the response of various ALT- or telomerase-positive cell lines to the ATR inhibitor VE-821. In addition, we compared the effect of the inhibitor on cell viability in isogenic cell lines, in which ALT was active or suppressed. In these experiments, a general ATR inhibitor sensitivity of cells with ALT could not be confirmed. We rather propose that the observed variations in sensitivity reflect differences between cell lines that are unrelated to ALT.

Keywords: alternative lengthening of telomeres, ataxia telangiectasia- and RAD3-related, ATR inhibitor, VE-821

INTRODUCTION

Cancer cells need to maintain their telomeres to avoid cellular senescence and apoptosis induced by the replicative shortening of chromosome ends. Frequently, expression of TERT, the protein subunit of telomerase, is reactivated to extend the telomeres. In addition, a significant fraction of tumors elongates the telomeres by an alternative lengthening of telomeres (ALT) pathway that operates via DNA repair and recombination processes as reviewed previously (1, 2). ALT is not known to occur in healthy cells and, thus, represents a unique feature of cancer cells that could be targeted with specific drugs.

A recent study investigated telomerase-positive and ALT-positive osteosarcoma and lung cancer cell lines as well as glioma stem cell lines and reported that cells that employ the ALT pathway are hypersensitive to the inhibition of the protein kinase ataxia telangiectasia- and RAD3-related protein (ATR), one of the two main DNA damage checkpoint-activating kinases in human cells (3). The authors concluded that treatment with the ATR inhibitor VE-821 selectively kills ALT cells within 6 days. They proposed that the immediate cell death induced by ATR inhibition in ALT cells is caused by an accumulation of DNA damage, aberrant anaphase chromosome...
segregation, and increased micronuclei formation. Yet, how ATR inhibition elicits these effects specifically in ALT cells to affect the short-term cell viability remains elusive. Previously, several studies have demonstrated that inhibiting telomerase or ALT will induce senescence or cell death, e.g., Ref. (4–7). However, in the latter work many population doublings over weeks and months were required to elicit this type of response. This long-term response is in line with the view that no significant effects on cell viability due to telomere shortening are expected to occur within a few days.

Here, we recapitulated the cell viability and FACS experiments by Flynn et al. using various ALT- or telomerase-positive cell lines. Additionally, we investigated whether suppression of ALT activity affects cell viability upon treatment with ATR inhibitor. In our study, no general hypersensitivity of ALT-positive cells toward ATR inhibitors was observed.

MATERIALS AND METHODS

Cell Culture

Validated U2OS, HeLa, CAL72, HCT116, and SAOS2 cells were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). The MG63 cell line was purchased from CLS Cell Lines Service (Eppelheim, Germany). U2OS, HeLa, and CAL72 cells were maintained in DMEM supplemented with 10% FCS, 2 mM l-glutamine, 1% antibiotics. For CAL72, 1X ITS liquid media supplement (Sigma-Aldrich) was added to this medium. The other three cell lines were cultured in 90% McCoy’s 5A supplemented with 10% FCS, 2 mM l-glutamine, and 1% antibiotics (HCT116), in 85% McCoy’s 5A supplemented with 20% FCS (SAOS2) or in DMEM/Ham’s F12 medium supplemented with 5% FCS, 2 mM l-glutamine, and 1% antibiotics (MG63). An U2OS cell line for inducible expression of ATRX (referred to here as U2OS\textsuperscript{ATRX-2}) was kindly provided by Richard Gibbons (University of Oxford, UK) and has been described previously (8). The U2OS\textsuperscript{ATRX-2} cells were cultured in DMEM supplemented with 10% doxycycline-free FCS, 2 mM l-glutamine, 1% antibiotics, 0.5 μg/ml puromycin, 0.7 μg/ml G418.

Cell Viability Assays

For cell viability assays, cells were seeded in triplicate in 96-well plates and incubated overnight. Different cell numbers were seeded to determine the cell number needed to obtain 70–90% confluency of the control sample after 6 days. Optional starting cell numbers for U2OS, HeLa, HCT116, and MG63 were 500 cells, and for CAL72 and SAOS2 1500 cells. The following day cells were either treated with DMSO (control) or with increasing concentrations (0.5, 1, 2, 4, 8, and 16 μM) of the ATR inhibitor VE-821 dissolved in DMSO. Three different batches were compared that included VE-821 as a predissolved 10 mM solution or as a powder obtained from Selleckchem as well as VE-821 in powder form from Calbiochem/Merck. The three different VE-821 batches yielded undistinguishable dose–response curves when compared for the same reference cell samples. The compound from Selleckchem was used for the experiments presented here. Cells were incubated for 6 days without medium change and cell viability was analyzed using CellTiter Glo (Promega) and a TECAN Infinite M200 plate reader according to the manufacturers’ instructions.

FACS Analysis of Cell Death

For analysis of cell death, cells were seeded in T25 flasks. Cell numbers were adjusted for each cell line to account for varying proliferation rates (1 × 10\(^6\) CAL72 cells, 1.4 × 10\(^6\) SAOS2 cells, and 0.8 × 10\(^6\) cells for HeLa, HCT116, and U2OS). The following day each cell line was either treated with 3 μM VE-821 (Selleckchem) or with the same volume of DMSO for the control samples. Cells were incubated for 6 days without medium change. Cells, including dead cells, were collected by trypsin and total cell numbers were determined using the LUNA cell counter (Biozym). Cells were resuspended in FACS binding buffer (10 mM HEPES, 2.5 mM CaCl\(_2\), 140 mM NaCl) at a final concentration of 2 × 10\(^6\) cells/ml, stained with FITC annexin V (BioLegend) and propidium iodide (Miltenyi Biotec) according to the manufacturers’ instructions, and analyzed by flow cytometry on a FACS Canto II (BD Biosciences). The fraction of apoptotic cells, characterized as annexin V positive, was quantified using the FACS Diva software. The percentage of induced cell death \(d_{\text{ind}}\) was calculated as

\[
d_{\text{ind}} = \frac{\text{percentage dead cells treated}}{\text{percentage dead cells control}} \times 100%.
\]

Generation and Analysis of a U2OS Cell Line with Inducible ATRX Expression

The pEGFP-C2-ATRX-HA plasmid was kindly provided by David Picketts (University of Ottawa, Canada) (9). ATRX-HA was amplified and cloned into the pTRE3G-ZSGreen1 vector (Clontech, USA) to construct pTRE3G-ZSGreen1-ATRX-HA for doxycycline-inducible expression of ATRX. Plasmids that contained the ATRX cDNA were propagated in the dam/dcm-negative bacterial strain JM110 (Agilent Technologies) to avoid transposon insertions. A stable U2OS\textsuperscript{ATRX-1} cell line was generated by transfecting U2OS cells with pCMV-Tet3G (Clontech, USA) and pTRE3G-ZSGreen1-ATRX-HA and subsequent selection with G418 (1 mg/ml). U2OS\textsuperscript{ATRX-1} cells were cultured under the same conditions as the parental U2OS cell line except that doxycycline-free FCS was used. For induction of ATRX expression, 1 μg/ml doxycycline was added to the medium and the expression was evaluated by western blotting. The following antibodies were used: anti-ATRX (Sigma, HPA001906), anti-HA (Abcam, ab18181), and anti-GAPDH (Ambion, AM4300). ALT activity after ATRX expression was evaluated by the C-circle assay and the number of ALT-associated PML bodies (APBs) as described previously (10). U2OS\textsuperscript{ATRX-1} (−) and U2OS\textsuperscript{ATRX-1} (+) cells were cultured in the absence or presence of 1 μg/ml doxycycline, respectively, for at least 7 days before treatment with ATR inhibitor. For the cell viability assay, 1000 cells of U2OS\textsuperscript{ATRX-1} (−) and U2OS\textsuperscript{ATRX-1} (+) were initially seeded and treated with inhibitor as described above. The same conditions were used for cell viability assays with the U2OS\textsuperscript{ATRX-2} cell line that, for
Cell viability of ALT- and telomerase-positive (TEL) cell lines upon treatment with the ATR inhibitor VE-821.

(Continued)
evaluating the ATRX rescued state, was induced with 0.4 μg/ml doxycycline for 7 days.

RESULTS AND DISCUSSION

To evaluate the sensitivity of cell lines to ATR inhibition, we compared the human telomerase positive (“TEL”) cell lines HeLa, HCT116, and MG63 with the ALT cell lines U2OS, CAL72, and SAOS2. Cell viability measurements after treatment with different ATR inhibitor concentrations were conducted using the CellTiter Glo assay (Promega) and by fluorescence-activated cell sorting (FACS) analysis with annexin V staining. The experimental methods and inhibitor treatment conditions of 6 days incubation without medium change were those used previously by Flynn et al. who also studied the MG63, U2OS, CAL72, and SAOS2 osteosarcoma cell lines (3).

Cell Viability Analysis with the CellTiter Glo Assay

In order to measure cell viability in response to VE-821, we first examined the HCT116 TEL cell line (Figure 1A) in reference to the original paper that characterized the VE-821 inhibitor (11). It is noted that the CellTiter Glo assay measures changes in the number of viable cells after inhibitor treatment relative to a control sample. Whether the resulting differences originate from a reduced growth rate or from an increase in cell death cannot be distinguished in this assay. The half-maximal inhibitory concentration (IC50) for the HCT116 cell line in our experiments was 1–2 μM and similar to that reported previously [see Figure S4D in Ref. (11)]. We note that the results were dependent on the amount of cells initially seeded (Figure 1A). Seeding higher cell numbers shifted the dose–response curve to elevated inhibitor concentrations. Consequently, the cells appeared less sensitive to the inhibitor. The same dependence was observed for the U2OS ALT cell line (Figure 1B). This behavior is likely to reflect the well-known differences between cell lines in terms of their proliferation rate as well as the dependence of this parameter on cell density. For example, cells can appear less sensitive to the ATR inhibitor when starting with higher cell numbers because the proliferating control cells reach confluency and stop dividing before the treatment ends after 6 days. By contrast, cells growing slower upon treatment may not reach confluency within 6 days and continue to proliferate during the complete observation period, albeit at a lower rate. Since values are normalized to the control, this would make the ratio of viable cells in treated versus control samples dependent on the density of seeded cells, the proliferation rate, and the observation time.

ATR Inhibitor Sensitivity of Different Cell Lines

For comparing ALT and TEL cell lines, we selected a starting cell number for each cell line that led to 70–90% confluency after 6 days in the absence of the inhibitor. The optimized starting cell numbers used for U2OS, HeLa, HCT116, and MG63 were 500 cells well for U2OS, HeLa, HCT116, and MG63 cell lines 1500 cells/well for the CAL72 and SAOS2 cell lines. Error bars represent SD of triplicate experiments. (D) IC50 concentrations determined from cell viability curves shown in panel C. (E) FACS analysis of cell death fraction in ALT and TEL cell lines treated with 3 μM VE-821 for 6 days in comparison to the DMSO control. Dead cells were determined by annexin V staining. Error bars represent SEM (n = 3). (F) Percentage of induced cell death determined from FACS analysis as in panel E. The induced cell death fraction was calculated as described in the section “Materials and Methods.”
large deletions in the ATRX gene was established. In the resulting U2OSATRX-1 cell line, HA-tagged ATRX protein is produced upon induction as confirmed by western blotting using an ATRX- and an HA-specific antibody (Figure 2A). The expression of ATRX protein progressively reduced ALT activity as apparent from monitoring two characteristic ALT markers: single-stranded circular C-rich extrachromosomal telomere repeats (C-circles) as well as PML-telomere colocalizations, termed APBs (13, 14). After 7 days of ATRX expression, the number of APBs was at the background level observed for TEL cell lines (Figure 2B) and C-circles were almost undetectable (Figure 2C) indicating a complete inhibition of ALT activity. Next, we compared the ATR inhibitor sensitivity of U2OSATRX-1 (+) cells that had ALT silenced due to ATRX induction to the same U2OS ATRX-1 (−) uninduced cell line with an active ALT pathway. The dose–response curves for the two cell samples were identical as determined with the CellTiter Glo assay (Figure 2D). In order to corroborate these results, we tested another U2OS cell line referred to here as U2OSATRX-2, which was also engineered to express ATRX upon doxycycline treatment and has been demonstrated to suppress ALT upon ATRX induction (8). In line with the data previously published by Clynes et al., 7 days of doxycycline treatment resulted in robust ATRX expression and suppression of the ALT pathway as indicated by the absence of C-circles (Figures 2E,F). Comparing the ATR inhibitor sensitivity of this cell line when ALT was active (no doxycycline) with the same cell line, in which ALT was suppressed (+doxycycline) yielded no differences (Figure 2G). The dose–response curves of the (un)induced U2OSATRX-1 and U2OSATRX-2 cells were indistinguishable within the error of the measurements. Thus, silencing ALT activity via ectopic expression of ATRX did not affect ATR inhibitor sensitivity of the cells.

**FIGURE 2 | ALT features and sensitivity to ATR inhibitor treatment upon ectopic expression of ATRX in ATRX-deficient U2OS cells.**

(Continued)
CONCLUSION

Ataxia telangiectasia- and RAD3-related and the protein kinase ataxia telangiectasia mutated (ATM) are the two main DNA damage checkpoint-activating kinases in human cells. Consistent with the view that replication stress and misguided DNA repair synthesis are crucial features of ALT, it was found that inhibition of ATR or ATM decreases ALT activity (3, 10, 17, 18). However, except for the Flynn et al. study, no immediate ALT-specific effects after ATR and/or ATM inhibition on cell viability and proliferation on the time scale of several days have been reported.

In our comparison of different cell lines, we identified a number of factors that affected the apparent sensitivity toward the VE-821 ATR inhibitor but were unrelated to ALT (Figure 1). These included the initial cell number seeded in relation to the proliferation rate as well as differences in the genetic background that may lead to an increased ATR inhibitor sensitivity independent of ALT. For example, the telomerase-positive HCT116 colon cancer cell line used here harbors a mutation in MRE11, which impairs binding to NBS1 and Rad50 and suppresses ATM activation in response to replication stress (19, 20). This may account for its relatively high sensitivity toward ATR inhibition in terms of cell viability independent of its telomere maintenance mechanism.

In addition to the effects of the above-mentioned factors, it would still be conceivable that the presence of ALT contributes to an increased sensitivity to ATR inhibition. To address this possibility, we compared two U2OS cell lines in which ALT was active with the same cell line that had ALT silenced by inducing ectopic ATRX expression. In these experiments, the ATR inhibitor sensitivity was not changed when the ALT pathway was rendered inactive (Figure 2). Thus, we conclude that cells that employ ALT to maintain their telomeres are not generally more sensitive to ATR inhibition than telomerase positive cells on the time scale of days. Rather we suggest that, as described above, the cell line-specific genetic background and additional factors exist that are responsible for the different cellular response to ATR inhibition.

Our results indicate that ATR inhibition alone will not be sufficient to target tumors in which ALT is active. Nevertheless, we share the view that the misguided DNA repair and recombination mechanism active in ALT provides unique novel options for anticancer therapies. In this context, the recurrent inactivation of the ATRX tumor suppressor protein in ALT cancer samples could be exploited (21). As inactive ATRX is associated with ALT-specific tumor features, it could, for example, be targeted by synthetic lethality approaches. In support of this conclusion, it has been recently shown that ATRX deficiency impairs non-homologous end joining and increases sensitivity to DNA damaging agents in a glioma mouse model (22). A systematic further investigation of this relation appears to be promising for exploiting ALT-associated cellular deregulation in personalized cancer therapies.

AUTHOR CONTRIBUTIONS

KD, IC, and CB conducted experiments. KD, IC, and KR designed research and analyzed the data. KR wrote the paper with contributions from KD and IC.

FUNDING

This work was supported within project CancerTelSys (01ZX1302) in the eMed program of the German Federal Ministry of Education and Research (BMBF).

REFERENCES

1. Conomos D, Pickett HA, Reddel RR. Alternative lengthening of telomeres: remodeling the telomere architecture. Front Oncol (2013) 3:27. doi:10.3389/fonc.2013.00027
2. Pickett HA, Reddel RR. Molecular mechanisms of activity and derepression of alternative lengthening of telomeres. Nat Struct Mol Biol (2015) 22(11):875–80. doi:10.1038/nsmb.3106
3. Flynn RL, Cox KE, Jeitany M, Wakimoto H, Bryll AR, Gamem NJ, et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science (2015) 347(6219):273–7. doi:10.1126/science. 1257216
4. Asai A, Oshima Y, Yamamoto Y, Uchida TA, Kusaka H, Akinaga S, et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res (2003) 63(14):3931–9.
5. Jiang WQ, Zhong ZH, Henson JD, Neumann AA, Chang AC, Reddel RR. Suppression of alternative lengthening of telomeres by Sp100-mediated sequestration of the MRE11/RAD50/NBS1 complex. Mol Cell Biol (2005) 25(7):2708–21. doi:10.1128/MCB.25.7.2708-2721.2005
6. Potts PR, Yu H. The SMCS/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins. Nat Struct Mol Biol (2007) 14(7):581–90. doi:10.1038/nsmb1259
7. Shay JW. Role of telomeres and telomerase in aging and cancer. Cancer Discov (2016) 6(6):584–93. doi:10.1158/2159-8290.CD-16-0062
8. Clynes D, Jellinska C, Xella B, Ayyub H, Scott C, Mitson M, et al. Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX. Nat Commun (2015) 6:7538. doi:10.1038/ncomms8538
9. Berube NG, Healy J, Medina CF, Wu S, Hodgson T, Jagla M, et al. Patient mutations alter ATRX targeting to PML nuclear bodies. Eur J Hum Genet (2008) 16(2):192–201. doi:10.1038/sj.ejhg.5201943
10. Osterwald S, Deeg KL, Chung I, Parisotto D, Würz S, Rohr K, et al. PML induces compaction, TRF2 depletion and DNA damage signaling at telomeres and promotes their alternative lengthening. J Cell Sci (2015) 128(10):1887–900. doi:10.1242/jcs.148296
11. Harper PM, Griffiths MR, Long JM, Charrier J-D, MacCormick S, Charlton PA, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol (2011) 7(7):428–30. doi:10.1038/ nchembio.573
12. Napier CE, Huschtscha LI, Harvey A, Bower K, Noble JR, Hendrickson EA, et al. ATRX represses alternative lengthening of telomeres. Oncotarget (2015) 6(18):16543–58. doi:10.18632/oncotarget.3846
13. Yeager TR, Neumann AA, English A, Huschtscha LI, Noble JR, Reddel RR. Telomerase-negative immortalized human cells contain a novel type of pro-myelocytic leukemia (PML) body. Cancer Res (1999) 59(17):4175–9.
14. Henson JD, Cao Y, Huschtscha LI, Chang AC, Au AY, Pickett HA, et al. DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol (2009) 27(12):1181–5. doi:10.1038/nbt.1587
15. Berube NG, Smeenk CA, Picketts DJ. Cell cycle-dependent phosphorylation of the ATRX protein correlates with changes in nuclear matrix and chromatin association. Hum Mol Genet (2000) 9(4):539–47. doi:10.1093/hmg/9.4.539
16. Mitson M, Kelley LA, Sternberg MJ, Higgs DR, Gibbons RJ. Functional significance of mutations in the Smn2 domain of ATRX. Hum Mol Genet (2011) 20(13):2603–10. doi:10.1093/hmg/ddr163
17. Nabetani A, Yokoyama O, Ishikawa F. Localization of hRad9, hHus1, hRad1, and hRad17 and caffeine-sensitive DNA replication at the alternative lengthening of telomeres-associated promyelocytic leukemia body. *J Biol Chem* (2004) 279(24):25849–57. doi:10.1074/jbc.M312652200

18. O’Sullivan RJ, Arnoult N, Lackner DH, Oganesian L, Haggblom C, Corpet A, et al. Rapid induction of alternative lengthening of telomeres by depletion of the histone chaperone ASF1. *Nat Struct Mol Biol* (2014) 21(2):167–74. doi:10.1038/nsmb.2754

19. Giannini G, Ristori E, Cerignoli F, Rinaldi C, Zani M, Viel A, et al. Human MRE11 is inactivated in mismatch repair-deficient cancers. *EMBO Rep* (2002) 3(3):248–54. doi:10.1093/embo-reports/krf044

20. Wen Q, Scorah J, Phear G, Rodgers G, Rodgers S, Meuth M. A mutant allele of MRE11 found in mismatch repair-deficient tumor cells suppresses the cellular response to DNA replication fork stress in a dominant negative manner. *Mol Biol Cell* (2008) 19(4):1693–705. doi:10.1091/mbc.E07-09-0975

21. Watson LA, Goldberg H, Berube NG. Emerging roles of ATRX in cancer. *Epigenomics* (2015) 7(8):1365–78. doi:10.2217/epi.15.82

22. Koschmann C, Calinescu AA, Nunez FJ, Mackay A, Fazal-Salom J, Thomas D, et al. ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. *Sci Transl Med* (2016) 8(328):328ra328. doi:10.1126/scitranslmed.aac8228

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2016 Deeg, Chung, Bauer and Rippe. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*